drugset / Trial / NCT00003434
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer that has been surgically removed.
Timeline
- Start
- 1998-06
- Primary completion
- 2002-08
- Completion
- 2002-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | carcinoembryonic antigen peptide 1 | Peptide | — | Intravenous |
| Background | Hepatitis B vaccine | Vaccine | — | Intravenous |